Cut Timelines And Costs In Late-Phase Oncology: Why Asia Should Be Your Next Trial Destination

As the global cancer burden continues to grow, there is an urgent need for promising and innovative oncology therapeutics. However, sponsors are also navigating competition for clinical trial sites, resources, and patients in the U.S., alongside the inherent patient recruitment and retention challenges associated with cancer drugs. To increase efficiency and reduce costs in the clinic, many sponsors are opting to expand their oncology trials into Asia.

Asia is home to a diverse patient population with an array of genetic profiles and disease patterns, including a high prevalence of lung, breast, gastric, and liver cancers. From a cost perspective, trials held in Asia typically cost 30% to 40% less than those held in the U.S. However, these lower costs do not denote reduced quality standards; countries like South Korea and Taiwan are home to world-class research centers and committed to good clinical practice (GCP) compliance. Download the full article to explore the benefits of conducting an oncology trial in Asia.